Advertisement

The Role of Risk Stratification in the Treatment of Well-Differentiated Thyroid Cancer

  • Kepal N. Patel

Abstract

The primary goal in the management of patients with well-differentiated thyroid cancer is to provide the best therapy with the least amount of morbidity. Initial therapy to remove all gross disease should be based on a risk adapted approach. The follow-up paradigm should incorporate the initial risk assessment, ongoing risk stratification, response to therapy variables, and disease-free survival. It is a dynamic process which helps ensure optimal patient care by allowing physicians to identify patients who are at high risk for disease recurrence. These patients may benefit from closer surveillance, testing, and treatment. More importantly, this dynamic risk adapted paradigm will help avoid over-treatment in patients who are at low risk of recurrence.

Keywords

Risk Stratification Staging Thyroid Cancer Prognosis Therapy 

References

  1. 1.
    Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104(6):947–53.PubMedGoogle Scholar
  2. 2.
    Cady B et al. Further evidence of the validity of risk group definition in differentiated thyroid carcinoma. Surgery. 1985;98(6):1171–8.PubMedGoogle Scholar
  3. 3.
    Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control. 2000;7(3):229–39.PubMedGoogle Scholar
  4. 4.
    Hay ID et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114(6):1050–7. Discussion 1057–8.PubMedGoogle Scholar
  5. 5.
    Lang BH et al. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007;245(3):366–78.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Mazzaferri EL, Jhiang SM. Differentiated thyroid cancer long-term impact of initial therapy. Trans Am Clin Climatol Assoc. 1995;106:151–68. Discussion 168–70.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol. 1996;3(6):534–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Sherman SI et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998;83(5):1012–21.CrossRefPubMedGoogle Scholar
  9. 9.
    Tuttle RM. Risk-adapted management of thyroid cancer. Endocr Pract. 2008;14(6):764–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Tuttle RM et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20(12):1341–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Tuttle RM, Fagin JA. Can risk-adapted treatment recommendations replace the ‘one size fits all’ approach for early-stage thyroid cancer patients? Oncology (Williston Park). 2009;23(7):592. 600, 603.Google Scholar
  12. 12.
    Rivera M et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol. 2010;23(9):1191–200.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Gupta S et al. Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse: distinct biologic and clinical entities. Arch Otolaryngol Head Neck Surg. 2012;138(3):227–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Liu J et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer. 2006;107(6):1255–64.CrossRefPubMedGoogle Scholar
  15. 15.
    Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569–80.CrossRefPubMedGoogle Scholar
  16. 16.
    Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2008;8(1):83–95.CrossRefPubMedGoogle Scholar
  17. 17.
    Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381(9871):1058–69.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184–99.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Xing M et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32(25):2718–26.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Liu X et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 2014;99(6):E1130–6.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Tuttle RM, Leboeuf R. Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinol Metab Clin North Am. 2008;37(2):419–35. ix–x.CrossRefPubMedGoogle Scholar
  22. 22.
    Tuttle RM, Leboeuf R, Shaha AR. Medical management of thyroid cancer: a risk adapted approach. J Surg Oncol. 2008;97(8):712–6.CrossRefPubMedGoogle Scholar
  23. 23.
    American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.CrossRefGoogle Scholar
  24. 24.
    Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447–63.CrossRefPubMedGoogle Scholar
  25. 25.
    Hay ID et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26(8):879–85.CrossRefPubMedGoogle Scholar
  26. 26.
    Bilimoria KY et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246(3):375–81. Discussion 381–4.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Shaha AR, Shah JP, Loree TR. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol. 1997;4(4):328–33.CrossRefPubMedGoogle Scholar
  28. 28.
    Castagna MG et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab. 2008;93(1):76–81.CrossRefPubMedGoogle Scholar
  29. 29.
    Chiovato L et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med. 2003;139(5 Pt 1):346–51.CrossRefPubMedGoogle Scholar
  30. 30.
    Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab. 2005;90(9):5047–57.CrossRefPubMedGoogle Scholar
  31. 31.
    Mazzaferri EL et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(4):1433–41.CrossRefPubMedGoogle Scholar
  32. 32.
    Spencer CA. Serum thyroglobulin measurements: clinical utility and technical limitations in the management of patients with differentiated thyroid carcinomas. Endocr Pract. 2000;6(6):481–4.PubMedGoogle Scholar
  33. 33.
    Toubeau M et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med. 2004;45(6):988–94.PubMedGoogle Scholar
  34. 34.
    Durante C et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Pacini F et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(8):3668–73.CrossRefPubMedGoogle Scholar
  36. 36.
    Robbins RJ, Larson SM. The value of positron emission tomography (PET) in the management of patients with thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2008;22(6):1047–59.CrossRefPubMedGoogle Scholar
  37. 37.
    Robbins RJ et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498–505.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Division of Endocrine Surgery, Department of SurgeryThyroid Cancer Interdisciplinary Program, NYU Langone Medical CenterNew YorkUSA

Personalised recommendations